Loading clinical trials...
Loading clinical trials...
There are nearly 300,000 patients with severe or intermediate thalassemia in China. Growth retardation is the most significant health issue for children and adolescents with transfusion-dependent thal...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
NCT03653338 · Sickle Cell Anemia, Beta-thalassemia Major, and more
NCT07112703 · Incentive Spirometer, Pulmonary Function, and more
NCT06490627 · Fetal Hemoglobin, Thalassemia Major, and more
NCT06734520 · Thalassemia Majors (Beta-Thalassemia Major), Haplo-identical Donors
NCT06466304 · Beta Thalassemia Major
Regenerative Medicine Center and Red Blood Cell Disorders Center
Tianjin, Tianjin Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions